Newamsterdam Pharma Company N.V. ( (NAMS) ) has released its Q1 earnings. Here is a breakdown of the information Newamsterdam Pharma Company N.V. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company based in the Netherlands, focusing on developing therapies for cardiometabolic diseases, with a primary emphasis on their CETP inhibitor, obicetrapib, aimed at lowering LDL-C levels in patients where current treatments are inadequate.